You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Model-Driven Strain Engineering for Isoprenoid Drug Production

    SBC: GENOMATICA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Engineering microbial strains with superior production capabilities is one of the most challenging and intriguing endeavors in bioprocess development. However, due to the lack of rational and systematic approaches, the timelines and cost for strain development can be large and at times prohibitive for many products. In this STTR, we will utilize an integrated c ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  2. Newborn Screening for Sex Chromosome Disorders

    SBC: JS GENETICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Turner syndrome (TS) is the most common genetic problem effecting women, with an incidence of 1 in 1,500 to 2,000 live female births and occurs when an entire, or portions of an X-chromosome is deleted. Phenotypic features include primary hypogonadism, renal abnormalities, and profound short stature. Yet, with growth hormone therapy, acceptable adult stature c ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  3. Lipid/DNA/Antigen Complexes for Influenza A Viral Vaccination

    SBC: JUVARIS BIOTHERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Influenza A (fluA) infection causes annual substantial morbidity and mortality worldwide, particularly for infants, the elderly, and the immuncompromised. FluA mainly replicates in the respiratory tract, with virulent strains also disseminating to other tissues, such as the central nervous system. A growing concern is the recent spread of virulent avian influen ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  4. A Genetic Test for Drug-Induced Dyskinesia Risk

    SBC: KOVOGEN            Topic: N/A

    DESCRIPTION (provided by applicant): The objective of this project is to develop a genetic test, involving the protein, RGS9, to identify patients that are at risk for developing tardive dyskinesia (TD) or L-DOPA induced dyskinesia (LID). Antipsychotic drugs have revolutionized the treatment of schizophrenia and psychotic disorders but a debilitating side-effect of "typical" antipsychotics is TD, ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  5. Antivirals Targeting Flavivirus Envelope Proteins

    SBC: L2 DIAGNOSTICS LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop therapeutic antivirals to treat life-threatening flavivirus infections. Enfuvirtide, a clinically successful peptide HIV fusion inhibitor, is the prototype for a new class of antivirals that inhibit viral envelope protein structural rearrangements essential for viral entry into host cells. In preliminary experiment ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  6. Broad-Spectrum Therapeutic Human Antibodies for Dengue Virus Infections

    SBC: L2 DIAGNOSTICS LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop antibody therapeutics to treat life-threatening flavivirus infections. Our working hypothesis is that antibodies recognizing specific, highly conserved envelope protein epitopes can prevent and treat infection by several different flaviviruses, including all four serotypes of dengue virus and West Nile virus (WNV). ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  7. A HUMAN MONOCLONAL COCKTAIL FOR RSV IMMUNOTHERAPY

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The central goal of this application is to develop a combination product comprising two fully human monoclonal antibodies (mAbs) produced in plants for the prevention of serious disease caused by respiratory syncytial virus (RSV). RSV causes high morbidity and mortality in certain neonate populations as well as in the elderly and in bone marrow transplant patie ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  8. ROMP-Derived Oligomers for Faciliated Synthesis

    SBC: MATERIA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This Phase I Small Business Technology Transfer study between Materia, Inc. and the University of Kansas is focused on the development of high-load, oligomeric reagents and scavenging agents derived from ring-opening metathesis polymerization (ROMP), one of several core metathesis technologies at Materia, Inc. The specific aims during Phase I focus on three are ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  9. Highly-Multiplexed Accurate HLA Typing using PAP and Digital Bead Technologies

    SBC: MAXWELL SENSORS INC.            Topic: N/A

    Highly-Multiplexed Accurate HLA Typing using PAP and Digital Bead Technologies

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  10. Vapor-based Manufacturing Multifunctional Coatings

    SBC: MICHIGAN CRITICAL CARE CONSULTANTS INC            Topic: N/A

    DESCRIPTION (provided by applicant): We propose a new manufacturing process for multifunctional coatings of biomedical implants. Towards this goal, polymer coatings applied by chemical vapor deposition (CVD) are exceptional candidates for the coating of implanted biomedical devices as indicated by their use in FDA approved drug-eluting stint (Cypher stint, J&J) uses a vapor-deposited polymer (pary ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government